Philip Seeman

1934 - 2021

country of citizenship: Canada

languages spoken, written or signed: English

educated at: McGill University, Baron Byng High School

occupation: pharmacologist, neuroscientist, pharmacist, neurophysiologist, university teacher

award received: Officer of the Order of Canada, Robert J. and Claire Pasarow Foundation Award for Distinguished Contributions to Neuropsychiatric Research, Fellow of the Royal Society of Canada

Philip Seeman, (8 February 1934 – 9 January 2021) was a Canadian schizophrenia researcher and neuropharmacologist, known for his research on dopamine receptors. Source: Wikipedia (en)

Series

There is nothing here

Create a new serie

Works

There is nothing here

Create a new work

Articles 63

Date

Title

Authors

2015-02-03

Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors

Philip Seeman
2015-11-19

Glutamate drug reduces dopamine inhibition of phosphorylation.

Philip Seeman
2012-07-01

Antipsychotic dosing: extended, and transient

Gary Remington, Philip Seeman
2011-12-01

Alzheimer's disease: β-amyloid plaque formation in human brain

Philip Seeman
2011-02-01

Antipsychotic drug binding in the substantia nigra: an examination of high metoclopramide binding in the brains of normal, Alzheimer's disease, Huntington's disease, and Multiple Sclerosis patients, and its relation to tardive dyskinesia

Philip Seeman
2011-11-03

Dopamine agonist radioligand binds to both D2High and D2Low receptors, explaining why alterations in D2High are not detected in human brain scans.

Philip Seeman
2011-11-29

Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia.

Philip Seeman
2010-09-23

The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia

Melissa L. Perreault, Philip Seeman
2010-09-02

Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization

Shitij Kapur, Philip Seeman
2010-09-07

"Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial

Shitij Kapur, Gary Remington, Philip Seeman, Steve Mann
2010-11-01

Exposure to nicotine produces an increase in dopamine D2(High) receptors: a possible mechanism for dopamine hypersensitivity

Gabriela Novak, Bernard Le Foll, Philip Seeman
2010-07-01

Cocaine self-administration markedly increases dopamine D2 receptor negative cooperativity for dopamine binding: A receptor dimer-based analysis

Rafael Franco, María S Aymerich, Philip Seeman
2010-10-01

Hyperactive mice show elevated D2(High) receptors, a model for schizophrenia: Calcium/calmodulin-dependent kinase II alpha knockouts

Gabriela Novak, Philip Seeman
2009-08

Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil

Philip Seeman
2009-10-01

The dopaminergic stabilizer ASP2314/ACR16 selectively interacts with D2(High) receptors

Kenichi Tokita, Philip Seeman
2009-10-01

Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2(High) receptor

Philip Seeman
2009-08-01

Glutamate agonists for treating schizophrenia have affinity for dopamine D2High and D3 receptors

Philip Seeman
2009-03-01

Glutamate receptor mGlu2 and mGlu3 knockout striata are dopamine supersensitive, with elevated D2(High) receptors and marked supersensitivity to the dopamine agonist (+)PHNO

Giuseppe Battaglia, Valeria Maria Gloria Bruno, Philip Seeman
2009-06-01

Increased dopamine D2High receptors in rats reared in social isolation

Madeleine V King, Philip Seeman
2009-05-01

Rats with persistently high exploratory activity have both higher extracellular dopamine levels and higher proportion of D(2) (High) receptors in the striatum.

Jaanus Harro, Aet Alttoa, Kadri Kõiv, Philip Seeman
2009-03-01

Dopamine D2High receptors measured ex vivo are elevated in amphetamine-sensitized animals

Philip Seeman
2008-02-01

Memantine agonist action at dopamine D2High receptors

Philip Seeman
2008-02-01

Dopamine partial agonist actions of the glutamate receptor agonists LY 354,740 and LY 379,268.

Philip Seeman
2008-11-01

Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia

Philip Seeman
2008-12-01

Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole

Philip Seeman
2008-05-01

Increase of dopamine D2(High) receptors in the striatum of rats sensitized to caffeine motor effects

Nicola Simola, Micaela Morelli, Philip Seeman
2008-03-04

Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery.

Shitij Kapur, Philip Seeman
2008-05-01

Dopamine D2(High) receptors moderately elevated by sertindole

Philip Seeman
2008-04-01

Dopamine D2(High) receptors on intact cells.

Philip Seeman
2008-04-01

Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans.

Shitij Kapur, Pablo Rusjan, Ariel Graff-Guerrero, Philip Seeman, Nathalie Ginovart
2007-03-01

"Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time

Shitij Kapur, Philip Seeman
2007-10-01

Kappa-opioid receptor stimulation quickens pathogenesis of compulsive checking in the quinpirole sensitization model of obsessive-compulsive disorder (OCD).

Melissa L. Perreault, Henry Szechtman, Philip Seeman

Human - wd:Q4419464

Welcome to Inventaire

the library of your friends and communities

learn more